Cargando…

Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report

PD-1/PD-L1 inhibitors activate immunological response and have become one of the main modalities of cancer treatment. However, they may result in the immune-related adverse events (irAEs). Immune-related cardiotoxicity is relatively rare but may become fatal. We will present a case of a male patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuanxiang, Hu, Yang, Yang, Bin, Jin, Caibao, Ren, Hui, Wu, Jingyi, Wang, Zhijun, Wei, Youying, Yang, Ling, Hu, Yanping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627268/ https://www.ncbi.nlm.nih.gov/pubmed/34848973 http://dx.doi.org/10.2147/OTT.S333242

Ejemplares similares

Bilateral endobronchial metastases from prostate cancer: A case report with literature review
por: Jin, Caibao, et al.
Publicado: (2020)

Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer
por: Ren, Hui, et al.
Publicado: (2019)

The incidence and prognosis of thymic squamous cell carcinoma: A Surveillance, Epidemiology, and End Results Program population-based study
por: Wu, Jingyi, et al.
Publicado: (2021)

A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient
por: Jin, Caibao, et al.
Publicado: (2021)

Cardiotoxicity of Contemporary Anticancer Immunotherapy
por: Dal’bo, Natalie, et al.
Publicado: (2020)

The broad spectrum of cardiotoxicities from immunotherapies
por: Iengo, Martina, et al.
Publicado: (2023)

Biomarkers of immunotherapy in non-small cell lung cancer
por: Wang, Lingling, et al.
Publicado: (2020)

Emerging immunotherapy targets in lung cancer
por: Zhu, Hao-Hua, et al.
Publicado: (2020)

Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy
por: Chen, Feihu, et al.
Publicado: (2023)

Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer
por: Zhu, Chennianci, et al.
Publicado: (2020)

LncRNA DLX6‐AS1 increases the expression of HIF‐1α and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR‐199a‐5p
por: Yang, Bin, et al.
Publicado: (2019)

Dramatic Response of Pulmonary Sarcomatoid Carcinoma to Nivolumab Combined with Anlotinib: A Case Report
por: Jin, Caibao, et al.
Publicado: (2020)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023)

Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021)

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2020)

Progress in immunotherapy for small cell lung cancer
por: Zhao, Dong, et al.
Publicado: (2020)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Huang, Lan, et al.
Publicado: (2020)

NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score
por: Song, Peng, et al.
Publicado: (2020)

Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature
por: Hu, Yang, et al.
Publicado: (2018)

International expert consensus on immunotherapy for early-stage non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2022)

Multi-dimensional evaluation of cardiotoxicity in mice following respiratory exposure to polystyrene nanoplastics
por: Zhang, Tianyi, et al.
Publicado: (2023)

Clinical definition of secondary resistance to immunotherapy in non‐small cell lung cancer
por: Huang, Dingzhi, et al.
Publicado: (2023)

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
por: Hu, Hui-Min, et al.
Publicado: (2018)

Immunotherapy for Non-Small Cell Lung Cancer
por: Yoon, Sung Ho
Publicado: (2014)

Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
por: Zhou, Suna, et al.
Publicado: (2023)

Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review
por: Khwaja, Raida M., et al.
Publicado: (2022)

The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment
por: Peng, Lei, et al.
Publicado: (2023)

Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin
por: Wang, Yingying, et al.
Publicado: (2020)

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review
por: Chan, Stefanie Ho Yi, et al.
Publicado: (2023)

Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology
por: Kersting, David, et al.
Publicado: (2022)

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs
por: Yang, Lu, et al.
Publicado: (2020)

Thoracic vertebral metastasis from progressive hepatocellular carcinoma following liver transplantation combined with resection of mesenteric and colonic metastases: A case report
por: Hu, Jingen, et al.
Publicado: (2020)

Postoperative thyroid crisis in an 11-year old male with McCune-Albright syndrome and atypical triiodothyronine hyperthyroidism: A case report
por: Hu, Jingen, et al.
Publicado: (2022)

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
por: Shen, Mo, et al.
Publicado: (2022)

Cardiotoxicity of Chemical Substances: An Emerging Hazard Class
por: Georgiadis, Nikolaos, et al.
Publicado: (2022)

Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges
por: Yang, Hui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5upb5l3sc358e0afmjhglq644h